- Obama ‘cavalier’ in hiding foreign aid order, judge rules
- Prince Charles: Muslims are driving Christians from Mideast through persecution
- Gitmo’s first commander: Close the prison down
- Google’s newest photography find: Just wink and shoot
- Detroit’s Heidelberg art project hit by 8 fires in 8 months
- Pa. police pull people over for random DNA tests for feds
- NASA pushing hard to get back into space game
- Harvard student to face federal charges for bomb hoax
- Ronnie Biggs of ‘Great Train Robbery’ fame dies, 84
- Pope Francis wins another ‘Person of the Year’ — from gay rights magazine
Novartis drug investigated after 11 deaths
LONDON (AP) - A European agency is investigating a multiple sclerosis drug made by industry giant Novartis to determine whether the medicine played any role in the deaths at least 11 patients.
The drug, Gilenya, was licensed last year in the European Union to treat a severe type of multiple sclerosis. It can cause a slow heart rate when first taken and doctors closely monitor patients after the first dose.
The European Medicines Agency, which is now investigating the drug, said it isn’t clear if it caused the deaths. One of the fatalities occurred in the United States, where a patient died within 24 hours of taking the first dose.
Novartis said not all the deaths were heart related.
A spokeswoman at the U.S. Food and Drug Administration said it also is conducting a data analysis but has not made any definitive conclusions and does not know when its review will be complete.
More than 30,000 patients have taken Gilenya worldwide.
The European Medicines Agency advised doctors to increase their monitoring of patients after the first dose of the medicine. The agency said the risk of a slow heart rate after the first dose of Gilenya was known when it was approved.
Novartis AG said it was advising doctors of new recommendations on using Gilenya. They had previously said all patients should be monitored for six hours after their first dose, but are now tightening that to include continuous heart monitoring using electrocardiograms and measuring blood pressure and heart rate every hour. In certain patients, that monitoring should be extended, the drug maker said in a statement.
This new guidance applies only to patients taking their first dose, Novartis said in a statement.
The EU drug regulator hopes to finish its review of the drug by March.
By John R. Bolton
The president fiddles at his domestic altar while the world burns
- U.S. Army mulls wiping out memory of Robert E. Lee, 'Stonewall' Jackson
- Top Democrats reject court ruling over NSA spying on Americans
- IRS pays tax cheats hundreds of millions of dollars
- HURT: D.C. gets the vapors, calls sequester too much
- BOLTON: Nero in the White House
- EDITORIAL: Al Gore, soothsayer
- Obama mocks Putin, picks gay athletes for Sochi delegation
- We told you so: Conservatives foresaw polygamy ruling
- Army to cut up to 4,000 captains and majors
- Rush weighs in: Maybe Republicans dont dislike Obamacare
Independent voices from the The Washington Times Communities
Southern Fried Politics from the Lens of a Persian-American Millennial
Wall Street news for retail investors who want to know what's going on.
Politics, economics, and business from a real world perspective.
Top 10 handguns in the U.S.
Extraordinary day at Redskins Park
White House pets gone wild!
Let it snow